Probiotic for Chronic Obstructive Airway Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Premier Medical Associates, The Villages, FL
Chronic Obstructive Airway Disease+6 More
Probiotic - DietarySupplement
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study aims to evaluate the impact of a specific oral probiotic blend on the quality of life of adults with respiratory conditions.

Eligible Conditions

  • Chronic Obstructive Airway Disease
  • Bronchiectasis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Chronic Obstructive Airway Disease

Study Objectives

1 Primary · 30 Secondary · Reporting Duration: 12 weeks

12 weeks
Change in Alanine Aminotransferase (ALT) after taking resB® Lung Support
Change in Albumin after taking resB® Lung Support
Change in Alkaline Phosphatase after taking resB® Lung Support
Change in Aspartate Aminotransferase (AST) after taking resB® Lung Support
Change in Bilirubin-total after taking resB® Lung Support
Change in Chloride after taking resB® Lung Support
Change in Creatinine after taking resB® Lung Support
Change in Estimated Glomerular Filtration Rate (eGFR) after taking resB® Lung Support
Change in Globulin after taking resB® Lung Support
Change in Hemoglobin levels after taking resB® Lung Support
Change in Mean Corpuscular Hemoglobin (MCH) after taking resB® Lung Support
Change in Mean Corpuscular Hemoglobin Concentration (MCHC) after taking resB® Lung Support
Change in Mean Corpuscular Volume (MCV) and Mean Platelet Volume (MPV) after taking resB® Lung Support
Change in Platelet count after taking resB® Lung Support
Change in Potassium after taking resB® Lung Support
Change in Reb Blood Cell (RBC) count after taking resB® Lung Support
Change in Sodium after taking resB® Lung Support
Change in Total Protein after taking resB® Lung Support
Change in Urea after taking resB® Lung Support
Change in White Blood Cell (WBC) count after taking resB® Lung Support
Change in White Blood Cell (WBC) differential after taking resB® Lung Support
Change in in Red Cell Distribution Width (RDW) after taking resB® Lung Support
Safety- adverse events
Safety- participants experiencing adverse events
To assess the safety and tolerability of resB® Lung Support in adult participants with chronic obstructive pulmonary disease or non-cystic fibrosis bronchiectasis
To determine the effect of resB® Lung Support on biomarkers of inflammation
To determine the effect of resB® Lung Support on gut microbiome
To determine the effect of resB® Lung Support on lung microbiome
To determine the effect of resB® Lung Support on quality of life
To determine the effect of resB® Lung Support on serum short-chain fatty acids
To determine the effect of resB® Lung Support on stool short-chain fatty acids

Trial Safety

Safety Progress

1 of 3

Other trials for Chronic Obstructive Airway Disease

Trial Design

2 Treatment Groups

Probiotic
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

50 Total Participants · 2 Treatment Groups

Primary Treatment: Probiotic · Has Placebo Group · N/A

Probiotic
DietarySupplement
Experimental Group · 1 Intervention: Probiotic · Intervention Types: DietarySupplement
Placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Probiotic
2013
Completed Phase 4
~3570

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks
Closest Location: Premier Medical Associates · The Villages, FL
Photo of florida 1Photo of florida 2Photo of florida 3
2022First Recorded Clinical Trial
0 TrialsResearching Chronic Obstructive Airway Disease
9 CompletedClinical Trials

Who is running the clinical trial?

ResBiotic Nutrition, Inc.Lead Sponsor
1 Previous Clinical Trials
22 Total Patients Enrolled
Nutrasource Pharmaceutical and Nutraceutical Services, Inc.NETWORK
26 Previous Clinical Trials
1,489 Total Patients Enrolled
Anthony Bier, MDStudy DirectorNutrasource Pharmaceutical and Nutraceutical Services
5 Previous Clinical Trials
260 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Use for at least 1 month prior to the first dose of study product: double-barrier method, intrauterine devices, or complete abstinence from sexual intercourse that can result in pregnancy.
You agree to refrain from treatments listed in the protocol in the defined timeframe.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.